Report : Middle East & Africa Acne Medication Market Forecast to 2030 - Regional Analysis - by Therapeutic Class (Retinoids, Benzoyl Peroxide, Antibiotics, Salicylic Acid, and Others), Formulation (Topical Medication and Oral Medication), Type (Prescription Medicine and Over-the-Counter Medicine), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Pharmacies and Drug Stores, Retail Stores, and E-Commerce)
At 3.6% CAGR, Middle East & Africa Acne Medication Market is Projected to be Worth US$ 548.39 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Middle East & Africa acne medication market was valued at US$ 415.25 million in 2022 and is expected to reach US$ 548.39 million by 2030, registering a CAGR of 3.6% from 2023 to 2030. Upsurge in need for organic & natural treatments and individualized treatment programs based on cutting-edge technologies & data-driven strategies are among the critical factors attributed to the Middle East & Africa acne medication market expansion.
As people are becoming more conscious of the potentially harmful effects of synthetic ingredients and chemicals used in traditional skincare products, the demand for natural and organic alternatives that are deemed to be safer, gentler, and more environmentally friendly is on the rise across the world. Consumers are increasingly seeking products free from harsh chemicals, artificial fragrances, and potentially irritating substances, opting for formulations that harness the power of plant-based ingredients, botanical extracts, essential oils, and other natural compounds known for their skincare benefits. In response to this trend, many skincare brands and manufacturers are developing a wide range of natural and organic acne treatment products that cater to the needs of health-conscious consumers. These products often feature ingredients such as tea tree oil, witch hazel, aloe vera, green tea extract, and salicylic acid derived from natural sources, offering a more holistic and sustainable approach to treating acne without compromising efficacy. In July 2022, MÁDARA, an organic skincare business, introduced two new and natural everyday skincare products—a microbiome-balancing moisturizer and a non-drying face cleanser. The company claims that these products were developed by blending science and nature and were specifically formulated to offer gentle treatment for people of different complexions, who are prone to acne. Both products are made with natural, organic, and vegan ingredients—Northern Juniper Stem Cells, fermented polysaccharides, and lichen and Maté tea extracts—which deal specifically with imperfections, keeping the skin unharmed. Adults and teenagers can both utilize this product. Thus, the increasing preference for natural and organic acne treatment options is expected to continue shaping the future of the Middle East & Africa acne medication market in the coming years.
The shift toward natural and organic acne treatment options is also driven by the increasing stringency of regulatory scrutiny and complications associated with industry standards. Regulatory agencies emphasize ingredient transparency, safety, and sustainability, prompting companies to reformulate their products to meet evolving consumer preferences for cleaner and greener skincare solutions. Thus, as more consumers prioritize natural ingredients and eco-friendly formulations in their skincare routines, the Middle East & Africa acne medication market is expected to experience new growth trends in the coming years.
On the contrary, side effects associated with acne medication hampers the growth of Middle East & Africa acne medication market.
Based on therapeutic class, the Middle East & Africa acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held 33.5% share of the Middle East & Africa acne medication market in 2022, amassing US$ 139.09 million. It is projected to garner US$ 201.78 million by 2030 to expand at 4.8% CAGR during 2023–2030.
In terms of formulation, the Middle East & Africa acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held 68.4% share of the Middle East & Africa acne medication market in 2022, amassing US$ 283.97 million. It is estimated to garner US$ 387.82 million by 2030 to expand at 4.0% CAGR during 2023–2030.
By type, the Middle East & Africa acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held 65.2% share of Middle East & Africa acne medication market in 2022, amassing US$ 270.56 million. It is predicted to garner US$ 368.58 million by 2030 to expand at 4.0% CAGR during 2023–2030.
Based on acne type, the Middle East & Africa acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held 54.7% share of the Middle East & Africa acne medication market in 2022, amassing US$ 227.15 million. It is projected to garner US$ 305.66 million by 2030 to expand at 3.8% CAGR during 2023–2030.
In terms of distribution channel, the Middle East & Africa acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held 49.6% share of the Middle East & Africa acne medication market in 2022, amassing US$ 206.07 million. It is estimated to garner US$ 287.53 million by 2030 to expand at 4.3% CAGR during 2023–2030.
Based on country, the Middle East & Africa acne medication market is categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held 32.4% share of Middle East & Africa acne medication market in 2022, amassing US$ 134.71 million. It is projected to garner US$ 189.58 million by 2030 to expand at 4.4% CAGR during 2023–2030.
Key players operating in the Middle East & Africa acne medication market are Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Galderma SA, Pfizer Inc, GSK Plc, and Viatris Inc., among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com